HC Wainwright Reiterates Buy Rating for PDS Biotechnology (NASDAQ:PDSB)

PDS Biotechnology (NASDAQ:PDSB)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $21.00 target price on the stock.

Several other equities analysts have also commented on PDSB. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. B. Riley dropped their price objective on PDS Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday, June 12th. One equities research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.25.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $3.07 on Tuesday. The company has a fifty day simple moving average of $3.37 and a 200-day simple moving average of $3.49. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The stock has a market cap of $112.60 million, a P/E ratio of -2.26 and a beta of 1.88.

PDS Biotechnology (NASDAQ:PDSB) last posted its earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same period last year, the business posted ($0.37) earnings per share. Equities analysts expect that PDS Biotechnology will post -1.3 EPS for the current fiscal year.

Institutional Trading of PDS Biotechnology

Several hedge funds have recently bought and sold shares of the stock. Inspirion Wealth Advisors LLC increased its position in PDS Biotechnology by 1.4% during the second quarter. Inspirion Wealth Advisors LLC now owns 359,894 shares of the company’s stock worth $1,054,000 after buying an additional 4,917 shares during the last quarter. Kathleen S. Wright Associates Inc. acquired a new stake in shares of PDS Biotechnology during the 1st quarter worth approximately $28,000. Tempus Wealth Planning LLC bought a new position in PDS Biotechnology in the second quarter valued at approximately $55,000. Ground Swell Capital LLC acquired a new position in PDS Biotechnology during the second quarter valued at approximately $67,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology during the second quarter worth $115,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.